Overview

As the Associate Director, Accounting, you will be part of a high performing and highly motivated finance team, with the primarily responsibility of supporting the Order to Cash (“OTC”) process and Ex-US Accounting and Reporting team, while managing the operations of our OTC strategy. You will support a team in Amsterdam and work with various internal and external groups requiring excellent cross-functional teamwork. In this role, you will work directly with senior management and will gain significant exposure throughout the organization, while supporting our growth and business goals as a key team member of our Accounting and Reporting team.

The successful candidate must not be afraid to crunch some numbers from SAP while maintaining a strategic mindset in implementing and enhancing our strategy. The ability to engage with both finance and non-finance stakeholders and connecting the dots on optimizing end-to-end processes will help you to exceed. A strong understanding in US GAAP and internal/external reporting is required. 

Note that this is a very “hands on role” that will provide the candidate the opportunity to manage and complete various projects, while gaining exposure to the overall US and Ex-US leadership teams. The ideal candidate must be willing to roll-up their sleeves and get into the details.

Key Responsibilities

• Supports an international team, with the ultimate responsibility to confirm that our business operations and Ex-US product revenue sales are accurately reported under US GAAP within SAP (ERP system) and internal/external reports.
• Actively leads and completes various projects, based on the applicable business and Accounting and Reporting needs, while working independently to find and implement solutions.
• Ensures team members remain motivated, challenged through learning opportunities and guided in their professional development with an effective coaching relationship.
• Builds close business relationships with the various commercial and market access teams and understands our pricing strategies and agreements for all products in each market.
• Works with senior leadership, both within Finance and outside of finance, on reporting our Gross-to-Net (“GTN”) accounting adjustments and changes in our pricing models, monthly.
• Business partner for our 3PL/4PL service providers, and finance representative for the overall OTC strategy.
• Process and SOX control owner for various key processes and related controls.
• Governance committee member and actively participates and leads certain ALNY Governance Committees.
• Oversees the execution of our Accounting and Reporting strategy and actively monitors and adjusts the strategy based on changes within the business.
• Oversees the month end close process and supports the team during the account reconciliation, while reviewing the Blackline and Auditboard tasks.
• Supports the Group and local statutory audits.
• Supports and mentors the overall Ex-US Accounting team and provides active guidance on various US GAAP and SOX related topics.

Qualifications

• Master’s degree in accounting and US C.P.A. certification required
• Proven leadership experience in public accounting (Big 4) (and private industry is preferred), with a minimum of 10+ years of accumulated experience (3+ years in an accounting leadership capacity required).
• Strong written and verbal communication, as well as presentation skills
• Detail-oriented and strong business analytical skills
• Positive attitude and strong work ethic  
• Strong technical skills including US GAAP and SEC reporting plus
• Proven experience in performing with cross-functional teams and projects to accomplish desired results, and confident in communicating with senior members of management
• Advanced Excel knowledge
• SAP experience a strong plus
• Strong command of English language (verbal and written)

#LI-LR1

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.